REGN logo

Regeneron Pharmaceuticals Inc. (REGN)

$957.76

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on REGN

Market cap

$99.08B

EPS

45.21

P/E ratio

18.4

Price to sales

4.95

Dividend yield

0.393%

Beta

0.098446

Price on REGN

Previous close

$952.40

Today's open

$952.56

Day's range

$946.94 - $965.48

52 week range

$591.52 - $991.73

Profile about REGN

CEO

Leonard S. Schleifer

Employees

15410

Headquarters

Tarrytown, NY

Exchange

Nasdaq Global Select

Shares outstanding

103447859

Issue type

Common Stock

REGN industries and sectors

Healthcare

Biotechnology & Life Sciences

News on REGN

US FDA approves Regeneron's drug for generalized myasthenia gravis

US FDA approves Regeneron's drug for generalized myasthenia gravis

news source

Reuters • 40 minutes ago

news preview

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals

news source

GlobeNewsWire • an hour ago

news preview

Regeneron Wins EC Clearance for Libtayo Dosing Flexibility

REGN gains EC approval for flexible Libtayo dosing across six cancer indications, potentially improving patient convenience and strengthening its oncology business.

news source

Zacks Investment Research • 4 hours ago

news preview

Regeneron Pharmaceuticals Sees Growth Ahead, Eyes EYLEA HD Syringe Approval

Regeneron Pharmaceuticals NASDAQ: REGN expects its three largest growth drivers to continue supporting revenue growth, while planning higher research and development spending and preparing for a specialty drug launch, executives said at the Jefferies Healthcare Conference.

news source

MarketBeat • Nov 17, 2026

news preview

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications

Approval introduces an extended dosing regimen of Libtayo 700 mg given every six weeks, following initial 12 weeks of treatment with Libtayo 350 mg every three weeks Also approved is an option of reducing subsequent infusion times of Libtayo 350 mg by up to half, from 30 minutes to 15 minutes, after a well-tolerated 30-minute infusion TARRYTOWN, N.Y., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) has approved an alternative, flexible dosing schedule for Libtayo® (cemiplimab) across all approved skin, lung and cervical cancer indications.

news source

GlobeNewsWire • Nov 17, 2026

news preview

REGN Price Forecast: Rally Faces Resistance After 37% Advance

Regeneron shares face growing resistance after a 37% advance, with potential correction targets emerging while the intermediate- and long-term bullish trends remain intact.

news source

FXEmpire • Nov 16, 2026

news preview

Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?

Regeneron sells 16 products, and they have helped revenue climb in recent years. The company's leading products delivered record revenue in the third quarter.

news source

The Motley Fool • Nov 14, 2026

news preview

POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms

Data presented today for the first time at the American Autonomic Society (AAS) annual meeting POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked increase in heart rate upon standing and associated orthostatic symptoms, with no FDA-approved treatments available A single dose of baloncibart reduced the exaggerated heart rate response to standing and improved orthostatic symptoms through four weeks; biomarker changes were consistent with plasma volume expansion, the intended effect of NPR1 blockade Potentially pivotal Phase 3 trial planned for first half of 2027 TARRYTOWN, N.Y., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results from the Phase 2 PINNACLE trial in adults with postural orthostatic tachycardia syndrome (POTS) evaluating baloncibart, a novel, investigational, first-in-class monoclonal antibody that blocks natriuretic peptide receptor 1 (NPR1).

news source

GlobeNewsWire • Nov 12, 2026

news preview

REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?

Regeneron's strong Eylea HD and Dupixent sales, expanding oncology portfolio and promising pipeline fuel growth prospects as Eylea faces intensifying competition.

news source

Zacks Investment Research • Nov 12, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Regeneron Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Regeneron Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in REGN on M1